IL232611A - 4-Amino-5-History (1-Benzothiophene-2-Yl) -Pyrollo [1,2- f] [4,2,1] Triazine, Preparation Process and Pharmaceutical Preparations Containing Them - Google Patents
4-Amino-5-History (1-Benzothiophene-2-Yl) -Pyrollo [1,2- f] [4,2,1] Triazine, Preparation Process and Pharmaceutical Preparations Containing ThemInfo
- Publication number
- IL232611A IL232611A IL232611A IL23261114A IL232611A IL 232611 A IL232611 A IL 232611A IL 232611 A IL232611 A IL 232611A IL 23261114 A IL23261114 A IL 23261114A IL 232611 A IL232611 A IL 232611A
- Authority
- IL
- Israel
- Prior art keywords
- benzothiophen
- pyrrolo
- amino
- preparation
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11193841 | 2011-12-15 | ||
| PCT/EP2012/074977 WO2013087578A1 (en) | 2011-12-15 | 2012-12-10 | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL232611A0 IL232611A0 (en) | 2014-06-30 |
| IL232611A true IL232611A (en) | 2017-05-29 |
Family
ID=47326168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL232611A IL232611A (en) | 2011-12-15 | 2014-05-14 | 4-Amino-5-History (1-Benzothiophene-2-Yl) -Pyrollo [1,2- f] [4,2,1] Triazine, Preparation Process and Pharmaceutical Preparations Containing Them |
Country Status (43)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10388493B2 (en) | 2011-09-16 | 2019-08-20 | Lam Research Corporation | Component of a substrate support assembly producing localized magnetic fields |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| ES2819398T3 (es) | 2013-07-18 | 2021-04-15 | Taiho Pharmaceutical Co Ltd | Agente terapéutico para el cáncer resistente al inhibidor de FGFR |
| DK3023100T3 (da) | 2013-07-18 | 2019-05-27 | Taiho Pharmaceutical Co Ltd | Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer |
| CN105940000B (zh) * | 2013-10-21 | 2019-12-24 | 盖诺斯克公司 | 取代的嘧啶化合物及其作为syk抑制剂的用途 |
| EP3229800A2 (en) * | 2014-12-11 | 2017-10-18 | Bayer Pharma Aktiengesellschaft | Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor |
| CA2978830A1 (en) | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| CN109311868B (zh) | 2015-12-22 | 2022-04-01 | 尚医治疗有限责任公司 | 用于治疗癌症和炎性疾病的化合物 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| JP7085985B2 (ja) | 2016-03-04 | 2022-06-17 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
| SG11201808582RA (en) | 2016-03-28 | 2018-10-30 | Incyte Corp | Pyrrolotriazine compounds as tam inhibitors |
| CN107513068A (zh) * | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
| BR112019012335A2 (pt) * | 2016-12-16 | 2020-03-03 | Cystic Fibrosis Foundation Therapeutics, Inc. | Derivados de heteroarila bicíclica como potenciadores de cftr |
| SG11201911929XA (en) | 2017-06-21 | 2020-01-30 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN111247150B (zh) * | 2017-08-15 | 2022-11-08 | 石药集团中奇制药技术（石家庄）有限公司 | Fgfr抑制剂及其医药用途 |
| WO2019034075A1 (zh) * | 2017-08-15 | 2019-02-21 | 南京明德新药研发股份有限公司 | Fgfr和egfr抑制剂 |
| CN111225907B (zh) | 2017-10-25 | 2023-05-26 | 拜耳制药股份公司 | 制备苯并噻吩-2基硼酸/硼酸盐的方法 |
| WO2019105734A1 (en) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
| AU2019239404B2 (en) | 2018-03-19 | 2021-12-23 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
| WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
| JP2022519081A (ja) | 2019-01-31 | 2022-03-18 | バイエル アクチェンゲゼルシャフト | ロガラチニブ塩酸塩の一水和物およびその固体状態 |
| AU2020220512B2 (en) * | 2019-02-15 | 2023-08-24 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | FGFR inhibitor compound in solid form and preparation method therefor |
| WO2020170355A1 (ja) * | 2019-02-20 | 2020-08-27 | 大鵬薬品工業株式会社 | Ｆｇｆｒ１変異腫瘍の治療方法 |
| CN109928976A (zh) * | 2019-02-26 | 2019-06-25 | 泰州亿腾景昂药业有限公司 | 一种工业化生产eoc317的方法 |
| CN114641293B (zh) * | 2019-11-08 | 2024-05-31 | 石药集团中奇制药技术（石家庄）有限公司 | 一种fgfr抑制剂的用途 |
| CN111004234A (zh) * | 2019-11-28 | 2020-04-14 | 湖南农业大学 | 一种2-苯基咪唑并[1,2-α]吡啶类化合物的C3位卤化方法 |
| CN117402161A (zh) * | 2022-07-06 | 2024-01-16 | 上海科恩泰生物医药科技有限公司 | 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1183033T3 (da) * | 1999-05-21 | 2006-06-06 | Bristol Myers Squibb Co | Pyrrolotriazininhibitorer af kinaser |
| PL354241A1 (en) | 1999-09-17 | 2003-12-29 | Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg | Kinase inhibitors as therapeutic agents |
| JPWO2004096806A1 (ja) * | 2003-04-30 | 2006-07-13 | 大日本住友製薬株式会社 | 縮合イミダゾール誘導体 |
| DE10327439A1 (de) * | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| AP2139A (en) | 2004-04-02 | 2010-08-21 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors. |
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| TW200635927A (en) * | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
| JP5116687B2 (ja) | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
| MY148491A (en) * | 2005-11-17 | 2013-04-30 | Osi Pharm Inc | FUSED BICYCLIC mTOR INHIBITORS |
| US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| JP5249776B2 (ja) | 2005-12-02 | 2013-07-31 | バイエル・ヘルスケア・エルエルシー | 過剰増殖性疾患および血管新生と関連する疾患を処置するために有用な置換された４−アミノ−ピロロトリアジン誘導体 |
| JP5193876B2 (ja) | 2005-12-02 | 2013-05-08 | バイエル・ヘルスケア・エルエルシー | オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体 |
| PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| CA2635231C (en) * | 2005-12-29 | 2014-07-15 | Abbott Laboratories | Protein kinase inhibitors |
| US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| US8765754B2 (en) | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
-
2012
- 2012-12-03 UY UY0001034484A patent/UY34484A/es unknown
- 2012-12-10 PE PE2014000926A patent/PE20141855A1/es active IP Right Grant
- 2012-12-10 SG SG11201402325QA patent/SG11201402325QA/en unknown
- 2012-12-10 US US14/365,424 patent/US20140336173A1/en not_active Abandoned
- 2012-12-10 EA EA201400707A patent/EA029556B1/ru not_active IP Right Cessation
- 2012-12-10 AU AU2012350750A patent/AU2012350750B2/en not_active Ceased
- 2012-12-10 KR KR1020147019406A patent/KR102057444B1/ko active IP Right Grant
- 2012-12-10 CA CA2859133A patent/CA2859133C/en active Active
- 2012-12-10 BR BR112014014531-8A patent/BR112014014531B1/pt active IP Right Grant
- 2012-12-10 MX MX2014006905A patent/MX367158B/es active IP Right Grant
- 2012-12-10 UA UAA201407930A patent/UA116768C2/uk unknown
- 2012-12-10 CU CU2016000039A patent/CU24426B1/es unknown
- 2012-12-10 MY MYPI2014701550A patent/MY178660A/en unknown
- 2012-12-10 SI SI201230702A patent/SI2791140T1/sl unknown
- 2012-12-10 WO PCT/EP2012/074977 patent/WO2013087578A1/en active Application Filing
- 2012-12-10 JP JP2014546445A patent/JP6050829B2/ja not_active Expired - Fee Related
- 2012-12-10 ES ES12798738.6T patent/ES2591203T3/es active Active
- 2012-12-10 EP EP12798738.6A patent/EP2791140B1/en active Active
- 2012-12-10 IN IN4310CHN2014 patent/IN2014CN04310A/en unknown
- 2012-12-10 PT PT127987386T patent/PT2791140T/pt unknown
- 2012-12-10 DK DK12798738.6T patent/DK2791140T3/en active
- 2012-12-10 HU HUE12798738A patent/HUE029582T2/en unknown
- 2012-12-10 ME MEP-2016-181A patent/ME02517B/me unknown
- 2012-12-10 PL PL12798738T patent/PL2791140T3/pl unknown
- 2012-12-10 RS RS20160733A patent/RS55144B1/sr unknown
- 2012-12-10 CN CN201280069882.6A patent/CN104245700B/zh active Active
- 2012-12-10 LT LTEP12798738.6T patent/LT2791140T/lt unknown
- 2012-12-12 JO JOP/2012/0377A patent/JO3295B1/ar active
- 2012-12-12 AR ARP120104679A patent/AR089207A1/es active Pending
- 2012-12-14 TW TW101147336A patent/TWI567076B/zh active
- 2012-12-14 US US13/715,553 patent/US9206184B2/en active Active
-
2014
- 2014-05-14 IL IL232611A patent/IL232611A/en active IP Right Grant
- 2014-06-09 CO CO14123802A patent/CO7030961A2/es unknown
- 2014-06-09 CU CUP2014000065A patent/CU20140065A7/es unknown
- 2014-06-10 DO DO2014000127A patent/DOP2014000127A/es unknown
- 2014-06-11 TN TNP2014000255A patent/TN2014000255A1/en unknown
- 2014-06-12 CL CL2014001547A patent/CL2014001547A1/es unknown
- 2014-06-12 EC ECIEPI20144722A patent/ECSP14004722A/es unknown
- 2014-06-13 PH PH12014501355A patent/PH12014501355A1/en unknown
- 2014-06-13 GT GT201400113A patent/GT201400113A/es unknown
- 2014-06-17 CR CR20140288A patent/CR20140288A/es unknown
- 2014-07-14 ZA ZA2014/05140A patent/ZA201405140B/en unknown
-
2015
- 2015-06-22 HK HK15105900.1A patent/HK1205123A1/xx not_active IP Right Cessation
-
2016
- 2016-08-31 CY CY20161100853T patent/CY1118112T1/el unknown
- 2016-09-02 HR HRP20161130TT patent/HRP20161130T1/hr unknown
-
2017
- 2017-07-17 AU AU2017206140A patent/AU2017206140A1/en not_active Abandoned
-
2018
- 2018-02-20 US US15/900,725 patent/US20190016724A1/en not_active Abandoned
-
2019
- 2019-06-18 AU AU2019204255A patent/AU2019204255A1/en not_active Abandoned
-
2021
- 2021-11-01 US US17/516,542 patent/US20220153745A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL232611A (en) | 4-Amino-5-History (1-Benzothiophene-2-Yl) -Pyrollo [1,2- f] [4,2,1] Triazine, Preparation Process and Pharmaceutical Preparations Containing Them | |
| IL266510B (en) | History of aminopyrimidines, their preparation and pharmaceutical preparations containing them | |
| IL229863A (en) | The history of pyramidine and pyridine, their preparation and their pharmaceutical preparations | |
| IL233441B (en) | Thiano[3,2-d] pyrimidine derivatives are protein kinase inhibitors, preparations containing them and their uses | |
| IL240877A0 (en) | History of triazolo [5,4-d] pyrimidine, their preparation and pharmaceutical preparations containing them | |
| PT3012258T (pt) | Composição farmacêutica compreendendo um derivado de pirazolo[1,5-a]pirimidina como agente antiviral | |
| IL231008A0 (en) | History of thiazoles, their preparation and pharmaceutical preparations containing them | |
| EP2661437A4 (en) | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO [2,3] PYRIMIDINE DERIVATIVES AS FAK / PYK2 INHIBITORS | |
| EP2857403A4 (en) | PYRROLO- [2,1-F -] [1,2,4-] TRIAZIN COMPOUND AND METHOD OF PREPARATION AND APPLICATION THEREOF | |
| ZA201301463B (en) | Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same | |
| IL231383A (en) | Reliable imidazole history, preparation and pharmaceutical preparations containing them | |
| EP2786998A4 (en) | THIENYL [3,] 2-D PYRIMIDIN-4-ON COMPOUNDS, METHOD OF MANUFACTURE, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | |
| IL227404A0 (en) | Pyrimidine history, their preparation and pharmaceutical preparations containing them | |
| IL232577A (en) | History of morpholinylbenzotriazine, their preparation and their pharmaceutical preparations | |
| EP2742020A4 (en) | N1-CYCLIC AMIN-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| EP2668186A4 (en) | PHARMACEUTICAL COMPOSITION WITH PYRIDIDE DERIVATIVES | |
| IL230219A0 (en) | History of dihydropyrazole, their preparation and pharmaceutical preparations containing them | |
| IL228705A (en) | Derivatives of Reliable Phenoxy-Ethyl, Pharmaceutical Preparations Containing and Using Them | |
| IL233199B (en) | History of heterocyclic carboxamides, their preparation and pharmaceutical preparations containing them | |
| IL248698A0 (en) | History of 1-h-pyrrolidine-4,2-dione and processes for their preparation | |
| ZA201309559B (en) | Comptothecin derivative, method for preparing same, pharmaceutical composition and use thereof | |
| EP2742946A4 (en) | PROCESS FOR THE PRODUCTION OF PYROSTEGIA VENUSTA DERIVATIVES, PYROSTEGIA VENUSTA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| IL221350A (en) | Preparations containing isocyanurate compounds, their preparation processes and coating compositions comprising them | |
| EP2668185A4 (en) | PHARMACEUTICAL COMPOSITION WITH PYRIDIDE DERIVATIVES | |
| IL228812A0 (en) | The history of Ecadsin, products and preparations containing them, their medical uses and methods of their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |